Bridging the Gap: Index Volume [International Conference on AIDS (12th: 1998: Geneva, Switzerland)]

12th World AIDS Conference

networks * new 131

-Keyword

Abstract

Keyword

Abstract--

ce areas/Collaborative
nd prevention/PHA
e challenge of national
veloping cross sectoral
nd its responsibility in
ds of measuring sexual
experience and support
a/Construction of local

of CDC-funded community-bas
and prevention/PHA
/Legal service provision for the p
in India: A case study from West
creation/The health team and it
of youth to model the social and
to assist parents in disclosing HI
for STDs and AIDS prevention a

nders/Stavudine stops neuro-AIDS in AZT-non-responders/Stav
- Chicago Consortium/ Neurocognitive function predicts employ
omplications in HIV/ complications in HIV/
us is not correlated with neurocognitive decline in HIV infection/B
e TMA assay, predicts outcomes as well as progr
egimens/Regression of impairment with protease
apy on HIV associated disorder/Change in CSF
s and HIV-1 associated neurodegeneration: Oncostatin-M produ
HIV infected population/ Neurologic manifestations in a Puertorica
e health care on Brazil/ disease's impact in people wit
iagnosis of HIV-related neurologic dysfunction/Evaluation of a pr
n cerebral spinal fluid/ Neurological symptoms during primary HI
e subjective perception/ and psychiatric disorders in
n HIV infected patients/ sensitive impairment in HIV i
e chain reaction (PCR)/ complications of HIV and cer
d from HIV patients with neurological diseases/Detection by nPC
ople/Oligosymptomatic patients in a cohort of HTLVNT) as markers of early deficit in asymptomatic HIV
nal fluid in patients with disturbances during advanc
ents with AIDS-related diseases/Cerebrospinal flui

34338
34355
34358
34374
42457
43470
60847
60973
564*/32207
24149
32208
32189
32195
32196
32198
32200
12181
22444
60697
12195
12449
22328
41156
22101
32205
32218
32222
42170

of patients treated with
abel study/Efficacy of
Managing the indinavir/
ter rescue therapy with
onavir, saquinavir, and
), didanosine (ddl) and
mbination" therapy with
etic interaction between
e intrapartum/neonatal
e efficacy and safety of
1/11 study of single dose
o lamivudine (3TC) and
sed therapy/NelfinavirPK) interaction between
mbination therapy with

(NVP) based combination ther
(NVP)+3TC+ZDV in nucleosid
interaction via US prescriber e
(NVP), indinavir (IDV), and lam
as a salvage regimen for indina
(NVP) as initial antiretroviral th
in a clinical practice/"Triple co
and indinavir and correlation wi
to reduce mother to infant HIV t
(NVP) in clinical practice: Expe
in HIV infected pregnant Ugan
(NVP) by direct analysis of plas
rescue therapy for patients faili
(NVP) and rifampin (RMP)/Ph
in treatment naive and experie

oop of HIV-1 gp120 and neuronal cells/Shared antigenic epitopes 32217
egion is reducing PC12 cell line viability/A pentapeptide 60334
ce apoptosis of primary neurons /Inflammatory cytokines and HIV- 32200
cupuncture regimen for neuropathic pain in HIV patients/Efficacy 60453
NTET Trial)/Peripheral neuropathy during stavudine-didanosine 12397
ciation with autonomic and CD4 count/Sexual dysfu 32125
d dementia and sensory /Predictive markers for HIV-a 560*/32191
and signs of peripheral in HIV infected children/Symp 32206
ent of painful peripheral in HIV+ individuals/Massage 42376
edicine (3G)/Control of, loss of appetite, skin infection 60259
surgery/lntraoperative neurophysiologic monitoring in aneurys 60016
and accommodation in neuropsychiatric institutions of psychiatri 44197
d antibodies (APL) and neuropsychologic tests (NT) as markers 32218
HIV+ men and women: Neuropsychological findings and psychol 60579
tion/Psychological and neuropsychological predictors of mortalit 595*/13345
gitudinal assessment of performance in HIV+ 24148
India/Serodiagnosis of neurotoxoplasmosis in India/Serodiagno 32223
cine designed for Asia/ Neutralizaion of macrophage and T cell lin 21214
hAfrican HIV-1 isolates/ Neutralization of South African HIV-1 isol 11176
nd their susceptibility to neutralization by polyclonal sera/Study of 11211
omain of gp120/Potent of primary HIV-1 isolates by 550*/21194
munoprecipitation and of HIV isolates by HIV patie 31110
s/Mechanism(s) of HIV by specific antibodies/Mec 31118
otent HIV-1 sera able to neutralize 17 primary HIV-1 isolates belon 31113
0 from the virion/Saliva neutralizes HIV-1 infection by displacing e 21143
on in northern Thailand/ Neutralizing antibody, plasma and cervica 23290
-1 infected individuals/ antibodies against HIV-1 pri 31109
f HIV-infected patients/ effect of secretory IgA to HIV 60770
individuals/Serum HIV neutralizing activity and IgA in exposed se 21124
munogenic and induces antibodies in macaques/Mult 21216
/Study of the impact of antibodies on the course of e 330*/31103

isk pregnant women in New Orleans, LA/Fear, low risk perceptio
mary care physicians in New York City/HIV/AIDS knowledge, attitu
eclining AIDS deaths in York City (NYC)/Protease inhibitors a
e use in HIV+ women in York State medicaid/Birth defects an
AIDS epidemic in Brazil/ trends in the AIDS epidemic in Brazil/
dining AIDS mortality in York City (NYC)/Declining AIDS mort
B subtypes in a Bronx, York community: A sentinel site for m
n selected HIV clinics in York City (NYC), 1991-97/Impact of t
STD) clinic attendees at Delhi/Epidemiological co-relates of H
n injecting drug users/ evidence to reconcile in vitro and epid
cohorts in Amsterdam, York and San Francisco, 1978-96/Lo
HIV-infected children in York City (NYC)/Aging cohort of perin
er sex among Asians in York City/HIV knowledge, condom us
tions: Puerto Ricans in York and Puerto Rico/Issues in studyi
dolescents in a slum of Delhi, India/Patterns and determinan
c and HIV risk in Papua Guinea/Love magic and HIV risk in P
g antiretroviral therapy/ perspective in the treatment of multi d
rganization (CBO) in York City/Patterns of antiretroviral us
ay men in London, UK/ therapies for HIV and sexual risk beha
and testing in Uganda/ relationships and HIV discordance rat
le exchange attenders/ sharing partners encounter places a:Injecting drug users in York City, 1991-1996/Decline in a ve
njection drug users in York City: A unique opportunity for pre
n 1993 through 1996 in Jersey/Evaluation of ZDV administrat
of injecting drug use, in York city/Fellatio continues to be ass
V infection rates among York State (NYS) prison entrants, 198
tudy of older children in York City, Los Angeles County, Mass
ree treatment facility in York City, 1993-1997/Increasingly di
ed medicaid patients in Jersey/Serious mental illness among
g on treatments issues/ needs for information and counselling
ed female sex workers/ HLA-A11 HIV-1 subtype E cytotoxic T
ecific T-cell cytotoxicity/ anti-HIV function: RANTES activity vi
re at Harlem Hospital in York City/Characteristics of HIV-infec
reatment programs in York/Co-locating and integrating com
arriers to condom use - advances in condom technology/Ove
can immigrants living in York City/Religion and HIV risk perce
can immigrants living in York City/Religion and HIV knowledg
S services 1998-2001/ York City's strategic plan for HIV/AID
ainst HIV/AIDS in Cuba/ alternative against HIV/AIDS in Cuba
ograms on the Internet: strategies in Mexico/AIDS prevention
imens submitted to the York City (NYC) Department of Healt
pecial needs plans in York State/Discussion of the process
primary care providers: antiretroviral treatment guidelines/W
ource limited countries/ developments in the treatment of HIV/
e at the AIDS Council of South Wales/The success of the vita
ate-based HIV testing/ testing technologies to enhance HIV p
prenatal care in Miami, York City, and Connecticut/Acceptan
ay and bisexual men in York City/HIV prevention/sex educati
lationships with men in Zealand/"Trust, love condoms": An H
t-based sex workers in York City/Give them what they need,
mmigrant population in York City/Project GOAL: Prevention i
care planning in the US/ HIV planning challenges: Technical a
s of a workgroup of the York State AIDS Advisory Council/Et
ntrolled environment in York State/Treatment education in pri
le living with HIV/AIDS: York State PWA Leadership Institute/
provement campaign - York State Department of Health AID
rison for HIV exposure/ and long-term injection drug users ris
he costs for HIV care?/ principals for treatment - How does it
s in Bangkok, Thailand/ injectors in the HIV epidemic among i
ction/Monitoring of the Zealand epidemic of AIDS and HIV inf
age for HIV treatment in York City/Inconsistencies in insuranc
iology of slow viruses: findings on human immunodeficiency
n HIV test in London/ treatments for HIV and sexual risk be
henomena in Poland/ prostitution phenomena in Poland/

12368
12369
12396
22337
22356
22357
22378
22404
23281
32248
41131
41209
60365
60623
60701
23298
12107
12280
12376
13170
13218
13225
13266
13290
13334
13357
175*/13363
14265
14297
14317
96*/14318
22125
22366
644*/23106
23149
23187
584*/23216
23228
23287
23407
23516
23529
23560
596*/24222
24332
603*/31127
31148
32418
32421
33112
33333
33336
34106
34307
34372
42116
42225
42231
42315
42375
43106
43142
43252
43282
43284
43326
43527
44125
44198
44292
60209
60271
60546
60570

60603
60640
60738
60809
60869

oconvertors have high activities with respect to the in
storation of HIV specific activity (NA) of HIV infected p
cine regimen/CTL and antibody responses with a co
odeficiency syndrome/ Neutropenia and bacterial infection in acq
bitors (PI)/Reversal of neutropenia in AIDS patients with CD4 cel
gy and natural history of in HIV disease/The aetiology
ulocyte reserve in AIDS by steroid challenge test to pr
ent of CMV infection in AIDS patients/A multicentre
reatment (HAART) on neutrophil and monocyte function/Effect
on polymorphonuclear neutrophils of individuals infected with HI
al activity in originating and monocytes from bone ma
n HIV infected patients/ Nevirapine /lamivudine drug-drug interacti
I combination therapy/ (NVP) + didanosine (DDI) + la
her HIV antiretrovirals/ has excellent blood brain barri
mbination therapy with nevirapine, zidovudine and a second nucl
cokinetic interactions of and ketoconazole/The pharm
wing "protease sparing" /nucleoside (NVP/nuc) combin
Stavudine-didanosine-: A convenient highly active tripl
idovudine (ZDV) and (NVP) can reduce CSF HIV-1 v
T), nelfinavir (NFV) and (NVP): Suppression of HIV-1 R
s/Once-daily dosing of: A retrospective, cross-study a

31105
31108
33221
22121
32149
32152
32153
32146
12322
31167
31187
12217
32393
60086
463*/12152
12218
12231
12239
12253
12275
12360

1/Characterization of a new long-term T-cell line SCHT persistentl

11159